Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 1/20 | 0.42 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17909864 | 0.91 | SYK (0.48) | SYKPARP1PIK3CBCYP1A2KDR | |
| SCHEMBL17909893 | 0.83 | SYK (0.41) | SYKPARP1PIK3CBCYP1A2KDR | |
| SCHEMBL17909883 | 0.78 | SYK (0.38) | SYKPARP1PIK3CBKDRTGFBR1 | |
| SCHEMBL17909822 | 0.78 | SLC2A1 (0.43) | PARP1PIK3CBKDRTGFBR1MAPK14 | |
| SCHEMBL17909840 | 0.76 | PARP1 (0.46) | PARP1PIK3CBCYP1A2KDRTGFBR1 | |
| SCHEMBL18426561 | 0.76 | AAK1 (0.39) | SYKPARP1PIK3CBKDRTGFBR1 | |
| SCHEMBL17909860 | 0.75 | NQO1 (0.42) | SYKPARP1KDRTGFBR1MAPK14 | |
| SCHEMBL27890736 | 0.75 | MKNK1 (0.46) | — | |
| SCHEMBL17909902 | 0.75 | F12 (0.47) | PARP1PIK3CB | |
| SCHEMBL17909846 | 0.74 | KDM4E (0.40) | SYKPARP1PIK3CBKDRTGFBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11021463-B2 | Therapeutic inhibitory compounds | ATTUNE PHARMACEUTICALS, INC. (US) | 2021-06-01 | — | — | US | disclosed |
| US-20200031800-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | ATTUNE PHARMACEUTICALS, INC. | 2020-01-30 | — | — | US | disclosed |
| US-20200031799-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | ATTUNE PHARMACEUTICALS, INC. | 2020-01-30 | — | — | US | disclosed |
| US-10266515-B2 | Therapeutic inhibitory compounds | LIFESCI PHARMACEUTICALS, INC. (BB) | 2019-04-23 | — | — | US | disclosed |
| US-10259803-B2 | Therapeutic inhibitory compounds | LIFESCI PHARMACEUTICALS, INC. (BB) | 2019-04-16 | — | — | US | disclosed |
| US-20180170906-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | ATTUNE PHARMACEUTICALS, INC. | 2018-06-21 | — | — | US | disclosed |
| US-20170260163-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | ATTUNE PHARMACEUTICALS, INC. | 2017-09-14 | — | — | US | disclosed |
| US-9611252-B2 | Therapeutic inhibitory compounds | LIFESCI PHARMACEUTICALS, INC. (BB) | 2017-04-04 | — | — | US | disclosed |
| US-20160200704-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | ATTUNE PHARMACEUTICALS, INC. | 2016-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200031800-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | KLKB1, SERPINB1, SERPINE1 | SYK 1810/4885PARP1 1139/4885PIK3CB 478/4885 |
| US-20200031799-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | KLKB1, SERPINB1, SERPINE1 | SYK 1810/4885PARP1 1139/4885PIK3CB 478/4885 |
| US-20180170906-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | KLKB1, SERPINB1, SERPINE1 | SYK 1810/4885PARP1 1139/4885PIK3CB 478/4885 |
| US-20170260163-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | KLKB1, SERPINB1, SERPINE1 | SYK 1810/4885PARP1 1139/4885PIK3CB 478/4885 |
| US-20160200704-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | KLKB1, SERPINB1, SERPINE1 | SYK 1810/4885PARP1 1139/4885PIK3CB 478/4885 |
| US-10266515-B2 | Therapeutic inhibitory compounds | KLKB1, SERPINB1, SERPINE1 | SYK 1810/4885PARP1 1139/4885PIK3CB 478/4885 |
| US-10259803-B2 | Therapeutic inhibitory compounds | KLKB1, SERPINB1, SERPINE1 | SYK 1810/4885PARP1 1139/4885PIK3CB 478/4885 |
| US-11021463-B2 | Therapeutic inhibitory compounds | KLKB1, SERPINB1, SERPINE1 | SYK 1810/4885PARP1 1139/4885PIK3CB 478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.